October 25, 2006 -- Etanercept (Enbrel) was the first biologic response modifier to enter the rheumatoid arthritis (RA) market, and it has always been a good seller. But recently, Amgen, which acquired the US rights when it bought Immunex, has been disappointed in the revenue increases for the drug. Meanwhile, Wyeth, which holds the ex-US rights, continues to experience double digit rates of growth. We look at the history and prospects for Enbrel...
